Artal Group’s Cardiff Oncology CRDF Stock Holding History

Artal Group’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-750,000	Closed	-$1.05M	–	125
2022 Q4	$1.05M	Hold	750,000	–	–	0.06%	104
2022 Q3	$1.16M	Hold	750,000	–	–	0.05%	108
2022 Q2	$1.65M	Hold	750,000	–	–	0.09%	105
2022 Q1	$1.86M	Hold	750,000	–	–	0.08%	114
2021 Q4	$4.51M	Hold	750,000	–	–	0.12%	109
2021 Q3	$5M	Hold	750,000	–	–	0.11%	113
2021 Q2	$4.99M	Hold	750,000	–	–	0.1%	117
2021 Q1	$6.95M	Sell	750,000 -150,000	-17%	-$1.82M	0.12%	116
2020 Q4	$16.2M	Hold	900,000	–	–	0.35%	67
2020 Q3	$12.8M	Buy	+900,000	New	+$5.94M	0.31%	70

Other funds holding CRDF

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Artal Group's CRDF Position: Q1 2023 in Review

Artal Group sold out of Cardiff Oncology (CRDF) in Q1 2023, closing a stake of 750,000 shares — an estimated $1.05M sold.

Artal Group first reported a position in CRDF in Q3 2020 and held it in 10 quarters. The position peaked at $16.2M in Q4 2020. 55 funds tracked by Wall St. Rank hold CRDF as of Q1 2023.

Artal Group reported no remaining Cardiff Oncology position as of Q1 2023 after selling out during the quarter.
Artal Group sold 750,000 Cardiff Oncology shares in Q1 2023, an estimated $1.05M.
Artal Group first reported a position in Cardiff Oncology in Q3 2020 and held it in 10 quarters.
Artal Group's Cardiff Oncology position peaked at $16.2M in Q4 2020.
55 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2023.

Based on Artal Group's 13F filing for Q1 2023, filed 12 May 2023.